Calytrix is developing treatments for myelofibrosis and essential thrombocythaemia, two rare blood disorders belonging to a group of conditions known as myeloproliferative neoplasms. The diseases are characterised by the overproduction of blood cells in the bone marrow and can lead to complications including bone marrow scarring and blood clots.
Lilly strikes another billion-dollar deal – 15 acquisitions this year alone
Eli Lilly is continuing its expansion strategy with the acquisition of blood cancer biotech Calytrix Bio in a deal worth up to USD 1.5 billion.
Advertisement